Page 14 - Pfizer

Pfizer to offer small Covid vax packaging to cut wastage of doses

US drug maker Pfizer aims to roll out smaller packages of its Covid-19 vaccine for public health departments and care providers by October, media reports said.

Pfizer Covid booster shot likely to start by Sep 20 in US, says Fauci

The US' booster shot campaign against Covid-19 will likely start with only the Pfizer vaccine from September 20, the country's top infectious disease expert has said

One Covid-19 vaccine makes more antibodies than another. Does it matter?

Now, subtle differences between the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines are emerging across patient groups over time.

Taiwan gets first Pfizer-BioNTech vaccines against Covid after long delay

Taiwan received its first batch of Pfizer-BioNTech vaccines Thursday after a prolonged purchasing process that gave rise to a political blame game with China

Covid vaccines may become a viable business, but that's not good news

Vaccines are not consumer products made by pharmaceutical industry: they are infrastructure.

New Zealand reports first death linked to Pfizer Covid-19 vaccine

An independent Covid-19 vaccine safety monitoring board considered that the woman's death was due to myocarditis, which is known to be a rare side effect of the Pfizer Covid-19 vaccine

'Pfizer jab side effects in 12-15 year olds at high risk, mild to moderate'

A new study has revealed that the side effects of the Pfizer-BioNTech jab against COVID-19 in 12-15-year-olds at high risk of complications from the infection are likely to be mild to moderate

US plans Covid-19 booster shots at six months instead of eight: Report

Pfizer and BioNTech have already started the application process for the approval of its booster shot in people 16 and older

Heart inflammation more common after Covid than Pfizer vaccine: Study

Pfizer's Covid vaccine has been linked with an increased risk of developing myocarditis -- a type of heart inflammation.

Pfizer seeking FDA approval for coronavirus vaccine booster dose

Pfizer is seeking US approval of a booster dose of its two-shot COVID-19 vaccine. The drugmaker said Wednesday that it has started the application process for a third dose of its vaccine for people ages 16 and older. The company said it will complete the application with the Food and Drug Administration by the end of this week. The company's move follows an announcement by U.S. health officials last week of plans to give COVID-19 booster shots to all Americans to shore up their protection amid the surging delta variant of the virus. Officials said it is very clear that the vaccines' protection against COVID-19 infections wanes over time. Pfizer's vaccine received full FDA approval earlier this week; it had been used since last December under an emergency use authorization. The three vaccines used in the U.S. made by Pfizer, Moderna and Johnson & Johnson are still preventing hospitalizations and deaths from COVID-19. But the vaccines don't appear quite as strong against the highly .

Explained: What FDA full approval to Pfizer-BioNTech vaccine means

The research to develop a safe and effective Covid-19 vaccine was accelerated in 2020

Fauci expects uptick in vaccine administration after FDA OKs Pfizer shot

Dr. Anthony Fauci says he's hoping for an uptick in the administration of Covid-19 vaccinations following US government approval of the Pfizer vaccine

US FDA grants full approval to Pfizer-BioNTech Covid vaccine

The FDA approved the two-dose vaccine for use in people over the age of 16.

Pfizer to acquire cancer drugmaker Trillium Therapeutics for $2.3 bn

Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement.

Pfizer and Astra vaccines less effective after 90 days, says study

The Oxford University study found that 90 days after a second shot of the Pfizer or Astra vaccine, their efficacy in preventing infections had slipped to 75 per cent and 61 per cent, respectively

Pfizer, AstraZeneca vaccines less effective against Delta variant: Study

The COVID vaccines by Pfizer and AstraZeneca are less effective against the Delta variant compared to the Alpha variant, according to a study led by researchers at the University of Oxford

Covid vaccines fight off infections but less effective against delta: Study

Results from UK survey are likely to fuel calls to give booster shots to the fully vaccinated.

Covid-19 pandemic: US okays third jab for those with low immunity

The amended emergency use authorization paves the way for people who have had an organ transplant, or those with a similar level of weakened immune system, to get an extra dose

Moderna Covid vaccine 76% effective against Delta, Pfizer 42%: Study

Covid-19 jabs that were developed by US drug makers Pfizer and Moderna may not be as effective against the 'Delta' variant compared to as they were against the original strain of the virus, says study

RDIF proposes Pfizer conduct joint trial with Sputnik Light as booster shot

The Russian Direct Investment Fund (RDIF) has proposed that US drugmaker Pfizer start joint trials with Sputnik Light as a booster COVID-19 vaccine shot, the RDIF said on Wednesday."Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix & match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster," it said in a Tweet.It further said that Sputnik V is the first in the world to offer combo trial to AstraZeneca in November 2020, co-sponsored mix & match trials with AstraZeneca, Moderna and Sinopharm."Sputnik V was the 1st in the world to offer combo trial to AstraZeneca in Nov 2020, co-sponsored mix & match trials with AstraZeneca, Moderna & Sinopharm. Since then heterogeneous boosting pioneered by Sputnik proved to be effective vs mutations," it added further.According to an official ...